Case Study: Effective Early Phase Oncology Study Design

Publications
Category:
Published on:
March 8, 2022
Written by:
Katell Bernois, Director Statistical Consulting

Background

As biostatistics consultants, we had the pleasure to support a biopharmaceutical company with the design of their Phase I/II study aimed at evaluating the safety, PK, and efficacy of their compound in advanced non-small cell lung cancer (NSCLC).  

The main objectives of the study were to:  

  • Investigate the safety profile  
  • Identify the Recommended Phase II Dose (RP2D)  
  • Gain preliminary evidence of anti-tumor activity 

Meeting study challenges 

The main challenge was optimizing the study design to consider the client needs—reasonable total number of enrolled patients and controlled study duration—while ensuring patient safety and close data follow-up.  

Additionally, the study needed to provide sufficient evidence to support further development and be used for regulatory purposes. 

Creating effective solutions 

Given the multiple objectives, the study was divided into three parts: dose-escalation, dose-expansion, and Phase II, each with different design elements using a Bayesian approach leveraging the accumulation of information during the trial.  

For the dose-escalation part to assess the RP2D, we implemented a Bayesian Optimal Interval (BOIN) design. BOIN design is as easy to implement and understand as traditional 3+3 designs and shows better performance equivalent to more complex model-based designs but without complexity. It optimizes the allocation of patients to effective dose levels while controlling for overdosing and considers the ongoing evaluation of toxicity for all treated patients when assigning dose levels to new patients. 

In addition, an accelerated titration phase, where dose escalation can be conducted after a single patient has been dosed at a dose level without any safety concern, was applied to minimize patient allocation to the lowest dose levels and reduce underdosing.  

For the dose-expansion part, a toxicity monitoring design following the same principle as dose escalation was implemented with stopping boundaries for overdose control based on dose-limiting toxicities. 

Finally, we implemented a Bayesian Optimal design for Phase II with efficacy monitoring based on Objective Response Rate (ORR) allowing more than one interim analysis while controlling the type I error and maximizing the study power under the null hypothesis for a given fixed sample size. Two interim looks were planned with stopping boundaries for futility based on ORR to ensure the study would only continue if the treatment was deemed promising. 

All design elements were based on target toxicity rate and ORR estimated from literature for similar products and available client data and simulations performed in R to assess different scenarios 

Outcomes 

By working with our biostatisticians and implementing a Bayesian Optimal design, we were able not only to ensure a successful FDA submission for the client, with the design being accepted as part of an IND submission but also to design a Phase I/II study that delivers quality data to guarantee patient safety.   

References

  • Liu S. and Yuan, Y. (2015). Bayesian optimal interval designs for phase I clinical trials, Journal of the Royal Statistical Society: Series C , 64, 507-523.Cancer Research, 24(18), 4357-4364.
  • Zhou, H., Lee, J. J., & Yuan, Y. (2017). BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints. Statistics in Medicine, 36: 3302-3314

Why choose Alira Health for your Biometrics?

Leveraging data as your key asset can maximize insights, increase quality and access, and decrease reporting timelines. Our team of biometrics experts works closely with you from start to finish delivering integrated solutions and reporting for regulatory submissions.

  • Leadership and guidance from an expert team of over 100 biostatisticians, data managers, statistical programmers, data scientists, and medical writers
  • Dedicated, experienced in-house data specialists, with an average of over 10 years of industry experience
  • Tiered governance approach designed to mitigate risks, guarantee quality, and improve the efficiency of project teams.

Related news

Events May 27, 2022
PSI 2022 Conference
We are pleased to announce that this year we will be joining PSI 2022 Conference, the principal annual event for statisticians in the pharmaceutical industry, as sponsors, exhibitors, and delegates.
Biometrics
Events May 19, 2022
DIA 2022 Global Annual Meeting
We are pleased to announce that we will be joining DIA 2022 Global Annual Meeting as exhibitors and delegates.
Biometrics Clinical Life Sciences Regulatory
Publications March 22, 2022
Biometrics: Industry State of Affairs
We spoke with Katell Bernois, Director of Statistical Consulting at Alira Health, to understand the key trends that are changing the biometrics industry.
Biometrics
Publications March 11, 2022
Addressing Common CDISC Compliance Findings for Regulatory Submission
Learn from the team of industry CDISC experts how to explain common SDTM/ADAM issues to regulatory reviewers.
Biometrics
Publications March 8, 2022
Case Study: Effective Early Phase Oncology Study Design
Discover more about how to use Bayesian Optimal Interval Design to effectively design an Early Phase Oncology study.
Biometrics
Publications March 8, 2022
White Paper: The Sequential Parallel Comparison Design for Reducing Placebo Response
In this white paper, we will explore a two-stage adaptive design called the “Sequential Parallel Comparison Design” (SPCD) for enrichment of placebo non-responders.
Biometrics
Events February 17, 2022
ACDM 2022
Join us at ACDM March 13-15 in Edinburgh, Scotland. Set up a meeting and speaking about how Alira Health can help you to accelerate innovation and deliver tomorrow’s standard of care.
Biometrics
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.